Transcriptomics and sequencing analysis of gene expression profiling for major depressive disorder

Area of Science:

• Neuroscience
• Genomics
• Psychiatry

Background:

• Major Depressive Disorder (MDD) is a prevalent psychiatric condition marked by persistent sadness and anhedonia.
• Transcriptome regulation, including mRNA processing and transport, is crucial for MDD alleviation.
• Aberrant RNA splicing and stability are recognized as key molecular determinants in MDD.

Purpose of the Study:

• To compare mRNA expression profiles across major depressive disorder (MDD) non-suicide, MDD with suicide (MDD-S), and control groups.
• To identify distinct gene expression patterns associated with different MDD phenotypes using RNA-Seq.
• To investigate potential molecular biomarkers for depression and suicide risk.

Main Methods:

• Transcriptomics and gene expression profiling via RNA-Sequencing.
• Analysis of 9 MDD patients, 10 MDD-S patients, and 10 control subjects.
• Comparative analysis of mRNA expression levels between the three groups.

Main Results:

• PRKACB gene was upregulated in MDD patients; GRM3, DLGAP1, and GRIA2 were downregulated, implicating the glutamatergic pathway.
• Five dopaminergic pathway genes (GRIA1, CAMK2D, PPP3CA, MAPK10, PPP2R2A) were downregulated in MDD-S patients compared to MDD and control groups.
• Cholinergic synapses showed alterations in MDD patients due to dysregulated genes (KCNQ5, PLCB4, ADCY9, CAMK2D, PIK3CA, GNG2) compared to controls.

Conclusions:

• The study provides novel insights into the molecular etiology of human depression.
• Identified specific gene expression changes in glutamatergic, dopaminergic, and cholinergic pathways associated with MDD and suicide risk.
• These findings highlight potential novel biomarkers for depression and suicide-associated conditions.